Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations

M. Alberti, E. Valoti, R. Piras, E. Bresin, M. Galbusera, C. Tripodo, F. Thaiss, G. Remuzzi, M. Noris

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are associated with mutations in genes encoding proteins of complement system (aHUS). We describe two patients with a clinical history of STEC-HUS, who developed end-stage renal disease (ESRD) soon after disease onset. They received a kidney transplant but lost the graft for HUS recurrence, a complication more commonly observed in aHUS. Before planning a second renal transplantation, the two patients underwent genetic screening for aHUS-associated mutations that revealed the presence of a heterozygous CFI mutation in patient #1 and a heterozygous MCP mutation in patient #2, and also in her mother who donated the kidney. This finding argues that the two cases originally diagnosed as STEC-HUS had indeed aHUS triggered by STEC infection on a genetic background of impaired complement regulation. Complement gene sequencing should be performed before kidney transplantation in patients who developed ESRD following STEC-HUS since they may be undiagnosed cases of aHUS, at risk of posttransplant recurrence. Furthermore, genetic analysis of donors is mandatory before living-related transplantation to exclude carriers of HUS-predisposing mutations. Two patients with a clinical history of D+ hemolytic uremic syndrome associated with Shiga-toxin-producing 0157:H7 E. coli and recurrence in the kidney graft carry heterozygous mutations in the genes encoding complement factor I (patient 1) and membrane cofactor protein (patient 2).

Original languageEnglish
Pages (from-to)2201-2206
Number of pages6
JournalAmerican Journal of Transplantation
Volume13
Issue number8
DOIs
Publication statusPublished - Aug 2013

Fingerprint

Shiga-Toxigenic Escherichia coli
Hemolytic-Uremic Syndrome
Recurrence
Mutation
Genes
Transplants
Kidney
Kidney Transplantation
Chronic Kidney Failure
Complement Factor I
CD46 Antigens
Shiga Toxins
Shiga Toxin
Escherichia coli
Hemolytic Anemia
Genetic Testing
Coinfection
Acute Kidney Injury
Thrombocytopenia
Transplantation

Keywords

  • Complement factor I
  • gene mutation
  • hemolytic uremic syndrome
  • kidney transplantation
  • membrane cofactor protein
  • Shiga-toxin

ASJC Scopus subject areas

  • Transplantation
  • Immunology and Allergy
  • Pharmacology (medical)

Cite this

Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations. / Alberti, M.; Valoti, E.; Piras, R.; Bresin, E.; Galbusera, M.; Tripodo, C.; Thaiss, F.; Remuzzi, G.; Noris, M.

In: American Journal of Transplantation, Vol. 13, No. 8, 08.2013, p. 2201-2206.

Research output: Contribution to journalArticle

@article{61c471e6d30e4f36a30aef3a8876b990,
title = "Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations",
abstract = "Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90{\%} of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10{\%} are associated with mutations in genes encoding proteins of complement system (aHUS). We describe two patients with a clinical history of STEC-HUS, who developed end-stage renal disease (ESRD) soon after disease onset. They received a kidney transplant but lost the graft for HUS recurrence, a complication more commonly observed in aHUS. Before planning a second renal transplantation, the two patients underwent genetic screening for aHUS-associated mutations that revealed the presence of a heterozygous CFI mutation in patient #1 and a heterozygous MCP mutation in patient #2, and also in her mother who donated the kidney. This finding argues that the two cases originally diagnosed as STEC-HUS had indeed aHUS triggered by STEC infection on a genetic background of impaired complement regulation. Complement gene sequencing should be performed before kidney transplantation in patients who developed ESRD following STEC-HUS since they may be undiagnosed cases of aHUS, at risk of posttransplant recurrence. Furthermore, genetic analysis of donors is mandatory before living-related transplantation to exclude carriers of HUS-predisposing mutations. Two patients with a clinical history of D+ hemolytic uremic syndrome associated with Shiga-toxin-producing 0157:H7 E. coli and recurrence in the kidney graft carry heterozygous mutations in the genes encoding complement factor I (patient 1) and membrane cofactor protein (patient 2).",
keywords = "Complement factor I, gene mutation, hemolytic uremic syndrome, kidney transplantation, membrane cofactor protein, Shiga-toxin",
author = "M. Alberti and E. Valoti and R. Piras and E. Bresin and M. Galbusera and C. Tripodo and F. Thaiss and G. Remuzzi and M. Noris",
year = "2013",
month = "8",
doi = "10.1111/ajt.12297",
language = "English",
volume = "13",
pages = "2201--2206",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "8",

}

TY - JOUR

T1 - Two patients with history of STEC-HUS, posttransplant recurrence and complement gene mutations

AU - Alberti, M.

AU - Valoti, E.

AU - Piras, R.

AU - Bresin, E.

AU - Galbusera, M.

AU - Tripodo, C.

AU - Thaiss, F.

AU - Remuzzi, G.

AU - Noris, M.

PY - 2013/8

Y1 - 2013/8

N2 - Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are associated with mutations in genes encoding proteins of complement system (aHUS). We describe two patients with a clinical history of STEC-HUS, who developed end-stage renal disease (ESRD) soon after disease onset. They received a kidney transplant but lost the graft for HUS recurrence, a complication more commonly observed in aHUS. Before planning a second renal transplantation, the two patients underwent genetic screening for aHUS-associated mutations that revealed the presence of a heterozygous CFI mutation in patient #1 and a heterozygous MCP mutation in patient #2, and also in her mother who donated the kidney. This finding argues that the two cases originally diagnosed as STEC-HUS had indeed aHUS triggered by STEC infection on a genetic background of impaired complement regulation. Complement gene sequencing should be performed before kidney transplantation in patients who developed ESRD following STEC-HUS since they may be undiagnosed cases of aHUS, at risk of posttransplant recurrence. Furthermore, genetic analysis of donors is mandatory before living-related transplantation to exclude carriers of HUS-predisposing mutations. Two patients with a clinical history of D+ hemolytic uremic syndrome associated with Shiga-toxin-producing 0157:H7 E. coli and recurrence in the kidney graft carry heterozygous mutations in the genes encoding complement factor I (patient 1) and membrane cofactor protein (patient 2).

AB - Hemolytic uremic syndrome (HUS) is a disease of microangiopathic hemolytic anemia, thrombocytopenia and acute renal failure. About 90% of cases are secondary to infections by Escherichia coli strains producing Shiga-like toxins (STEC-HUS), while 10% are associated with mutations in genes encoding proteins of complement system (aHUS). We describe two patients with a clinical history of STEC-HUS, who developed end-stage renal disease (ESRD) soon after disease onset. They received a kidney transplant but lost the graft for HUS recurrence, a complication more commonly observed in aHUS. Before planning a second renal transplantation, the two patients underwent genetic screening for aHUS-associated mutations that revealed the presence of a heterozygous CFI mutation in patient #1 and a heterozygous MCP mutation in patient #2, and also in her mother who donated the kidney. This finding argues that the two cases originally diagnosed as STEC-HUS had indeed aHUS triggered by STEC infection on a genetic background of impaired complement regulation. Complement gene sequencing should be performed before kidney transplantation in patients who developed ESRD following STEC-HUS since they may be undiagnosed cases of aHUS, at risk of posttransplant recurrence. Furthermore, genetic analysis of donors is mandatory before living-related transplantation to exclude carriers of HUS-predisposing mutations. Two patients with a clinical history of D+ hemolytic uremic syndrome associated with Shiga-toxin-producing 0157:H7 E. coli and recurrence in the kidney graft carry heterozygous mutations in the genes encoding complement factor I (patient 1) and membrane cofactor protein (patient 2).

KW - Complement factor I

KW - gene mutation

KW - hemolytic uremic syndrome

KW - kidney transplantation

KW - membrane cofactor protein

KW - Shiga-toxin

UR - http://www.scopus.com/inward/record.url?scp=84881374227&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881374227&partnerID=8YFLogxK

U2 - 10.1111/ajt.12297

DO - 10.1111/ajt.12297

M3 - Article

C2 - 23731345

AN - SCOPUS:84881374227

VL - 13

SP - 2201

EP - 2206

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 8

ER -